Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Up 7%+ on no volume so once we get good news here this extreme low float gem will go through the roof
TRVI=MC $49 M/Cash $53 M /Phase 3 Data soon =this extreme low float stock could explode toward $10 and more on positive results .GL
Trevi Therapeutics (TRVI)
Market Cap: $49 Million
Cash: $53 Míllion (or untill Q4 2021)
Price: $2.79
Shares Out: 17.8 Million
Company Presentation
https://ir.trevitherapeutics.com/static-files/53d9afd8-eb64-40ca-b40b-6dc102f91b67
Major Shsareholders:
TPG Capital, L.P...6.3M
New Enterprise ...5.9M
Omega Fund ...1.3M
Lundbeckfond ...1.2M
Fidelity ...792.7K
Franklin ...587.3K
Richard King ...347.2K
Meeker (David P)...311.8K
Good (Jennifer L)...206.2K
Sciascia (Thomas R)...193.7K
BMO Capital Markets analyst Gary Nachman initiated coverage of shares of Trevi with an Outperform rating and $15 price target.
The Thesis
Trevi's key product Nalbuphine ER has a solid track record and substantial evidence supporting its mechanism of treating various chronic pruritus and cough conditions, analyst Nachman said in a Monday morning note.
Nalbuphine ER is an oral formulation of Nalbuphine, an injectable in use for decades to treat pain, and it is the only opioid-based pain drug not scheduled by the DEA, the analyst added.
The pipeline asset has shown positive clinical data in a large Phase 2b/3 trial in uremic pruritus associated with chronic kidney disease, and in a smaller Phase 2 study in prurigo nodularis, the lead indication, the asset achieved statistical significance in a post-hoc analysis for patients who completed the study on the higher dose, Nachman noted.
The analyst said prurigo nodularis is an area of high unmet need with a sizeable market opportunity.
A larger Phase 2b/3 study for the lead indication for which enrollment has begun, according to the analyst, has a good chance of success. Data from the study is expected in the first half of 2020, he added.
"We see a compelling valuation at current levels after recent IPO, with further optionality for Nalbuphine ER in additional indications beyond PN," BMO concluded.
One of the cheapest biotech you can get at this time .STRONG BUY
TRVI=MC $49 M/Cash $53 M /Phase 3 Data soon =this extreme low float stock could explode toward $10 and more on positive results .GL
Trevi Therapeutics (TRVI)
Market Cap: $49 Million
Cash: $53 Míllion (or untill Q4 2021)
Price: $2.79
Shares Out: 17.8 Million
Company Presentation
https://ir.trevitherapeutics.com/static-files/53d9afd8-eb64-40ca-b40b-6dc102f91b67
Major Shsareholders:
TPG Capital, L.P...6.3M
New Enterprise ...5.9M
Omega Fund ...1.3M
Lundbeckfond ...1.2M
Fidelity ...792.7K
Franklin ...587.3K
Richard King ...347.2K
Meeker (David P)...311.8K
Good (Jennifer L)...206.2K
Sciascia (Thomas R)...193.7K
BMO Capital Markets analyst Gary Nachman initiated coverage of shares of Trevi with an Outperform rating and $15 price target.
The Thesis
Trevi's key product Nalbuphine ER has a solid track record and substantial evidence supporting its mechanism of treating various chronic pruritus and cough conditions, analyst Nachman said in a Monday morning note.
Nalbuphine ER is an oral formulation of Nalbuphine, an injectable in use for decades to treat pain, and it is the only opioid-based pain drug not scheduled by the DEA, the analyst added.
The pipeline asset has shown positive clinical data in a large Phase 2b/3 trial in uremic pruritus associated with chronic kidney disease, and in a smaller Phase 2 study in prurigo nodularis, the lead indication, the asset achieved statistical significance in a post-hoc analysis for patients who completed the study on the higher dose, Nachman noted.
The analyst said prurigo nodularis is an area of high unmet need with a sizeable market opportunity.
A larger Phase 2b/3 study for the lead indication for which enrollment has begun, according to the analyst, has a good chance of success. Data from the study is expected in the first half of 2020, he added.
"We see a compelling valuation at current levels after recent IPO, with further optionality for Nalbuphine ER in additional indications beyond PN," BMO concluded.
What about the $4 BILLION DEBT and the annual Cash burn of almost $2 BILLION ?? Looks like the company is finished
SNGX =MC $52M--BREAKOUT---3x Phase 3 Programs +Covid 19 Vaccine data soon ..Dirt cheap stock with huge upside potential
SNGX =BREAKOUT ---and stilla mega bargain at 57 million valuation
SNGX =MC $46 M--Moving higher could breakout anytime now
SNGX =Mcap $45 M---3x Phase 3 programs+ COVID 19 Vaccine data soon=one of the cheapest biotech out there
COVID-19 Vaccine; Zacks Small-Cap Research Increases Valuation To $12.00 Per Share
https://finance.yahoo.com/news/soligenix-inc-heat-stabilization-platform-131100640.html
Presentation
http://ir.soligenix.com/download/Soligenix+Corporate+Presentation+04.30.20.pdf
SNGX =MC $46 M--Moving higher could breakout anytime now
SNGX =Mcap $45 M---3x Phase 3 programs+ COVID 19 Vaccine data soon=one of the cheapest biotech out there
COVID-19 Vaccine; Zacks Small-Cap Research Increases Valuation To $12.00 Per Share
https://finance.yahoo.com/news/soligenix-inc-heat-stabilization-platform-131100640.html
Presentation
http://ir.soligenix.com/download/Soligenix+Corporate+Presentation+04.30.20.pdf
SNGX =Mcap $45 M-COVID 19 Vaccine data soon ..Could run like NVAX did from $3 to $60
COVID-19 Vaccine; Zacks Small-Cap Research Increases Valuation To $12.00 Per Share
https://finance.yahoo.com/news/soligenix-inc-heat-stabilization-platform-131100640.html
SNGX =Mcap $45 M-COVID 19 Vaccine data soon ..Could run like NVAX did from $3 to $60
COVID-19 Vaccine; Zacks Small-Cap Research Increases Valuation To $12.00 Per Share
https://finance.yahoo.com/news/soligenix-inc-heat-stabilization-platform-131100640.html
SNGX =MC $43 M -CHEAPEST Covid 19 Vaccine gem starts RUNNINGGG
SNGX =CHEAPEST Covid 19 gem starts RUNNINGGGG
SNGX =Price $1.58--Mcap $40 M-- COVID 19 Vaccine data soon ..DIRT cheap Corona gem which has potential to be the next NVAX
Soligenix Inc. Heat-Stabilization Platform Evaluating Use With COVID-19 Vaccine; Zacks Small-Cap Research Increases Valuation To $12.00 Per Share
https://finance.yahoo.com/news/soligenix-inc-heat-stabilization-platform-131100640.html
SNGX =Price $1.58--Mcap $40 M-- COVID 19 Vaccine data soon ..DIRT cheap Corona gem which has potential to be the next NVAX
Soligenix Inc. Heat-Stabilization Platform Evaluating Use With COVID-19 Vaccine; Zacks Small-Cap Research Increases Valuation To $12.00 Per Share
https://finance.yahoo.com/news/soligenix-inc-heat-stabilization-platform-131100640.html
BMRA =MC $80 M-COVID 19 Test approved = Could run like CODX which is valued at $700+ million .
Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution
https://www.globenewswire.com/news-release/2020/05/07/2029243/0/en/Biomerica-Receives-CE-mark-for-New-High-Volume-Version-of-10-Minute-Test-for-COVID-19-Exposure-and-Expands-International-Distribution.html
BMRA =MC $80 M-COVID 19 Test approved = Could run like CODX which is valued at $700+ million .
Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution
https://www.globenewswire.com/news-release/2020/05/07/2029243/0/en/Biomerica-Receives-CE-mark-for-New-High-Volume-Version-of-10-Minute-Test-for-COVID-19-Exposure-and-Expands-International-Distribution.html
ITP = Price 0.57-MC $12 M--UNKNOWN corona gem ..could breakout today
ITP = Price 0.57-MC $12 M--UNKNOWN corona gem ..could breakout today
ITP= Price 0.50--MC $11 M --HOT Corona gem..Share offering created a great buying opp today
IT Tech Packaging, Inc. Launches Production of Single-Use Face Masks for COVID-19 Protection
https://finance.yahoo.com/news/tech-packaging-inc-launches-production-120000599.html
ITP= Price 0.50--MC $11 M --HOT Corona gem..Share offering created a great buying opp today
IT Tech Packaging, Inc. Launches Production of Single-Use Face Masks for COVID-19 Protection
https://finance.yahoo.com/news/tech-packaging-inc-launches-production-120000599.html
ITP= Price 0.50--MC $11 M --HOT Corona gem..Offering today created a mega buying opp
IT Tech Packaging, Inc. Launches Production of Single-Use Face Masks for COVID-19 Protection
https://finance.yahoo.com/news/tech-packaging-inc-launches-production-120000599.html
ITP= Price 0.50--MC $11 M --HOT Corona gem..Offering today created a mega buying opp
IT Tech Packaging, Inc. Launches Production of Single-Use Face Masks for COVID-19 Protection
https://finance.yahoo.com/news/tech-packaging-inc-launches-production-120000599.html
ITP= Price 0.50--MC $11 M --HOT Corona gem..Offering today created a mega buying opp
IT Tech Packaging, Inc. Launches Production of Single-Use Face Masks for COVID-19 Protection
https://finance.yahoo.com/news/tech-packaging-inc-launches-production-120000599.html
ITP= Price 0.50--MC $11 M --HOT Corona gem
IT Tech Packaging, Inc. Launches Production of Single-Use Face Masks for COVID-19 Protection
https://finance.yahoo.com/news/tech-packaging-inc-launches-production-120000599.html
PULM = NOW RUNNINGGG
PULM =Price $1.38 --HOT Corona gem --low valuation of ust $28 million..Up 10% could breakout to $2++ anytime now
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19
https://finance.yahoo.com/news/pulmatrix-sensory-cloud-announce-partnership-123000529.html
PULM =Price $1.38 --HOT Corona gem --low valuation of ust $28 million..Up 10% could breakout to $2++ anytime now
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19
https://finance.yahoo.com/news/pulmatrix-sensory-cloud-announce-partnership-123000529.html
PULM -Price $1.82 (New Corona gem) MEGA breakout imminent guys could run to $5++ fast
PULM= Price $1.70--NEW UNKNOWN CORONA GEM could hit $5++ quickly
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19---April 16, 2020
https://finance.yahoo.com/news/pulmatrix-sensory-cloud-announce-partnership-123000529.html
PULM =NEW Corona gem could explode toward $5++ very fast once it breaks the $2 mark